Song P, He J, Li F, Jin C. Innovative measures to combat rare diseases in China: the national rare diseases registry system, larger-scale clinical cohort studies, and studies in combination with precision medicine research. Intractable Rare Dis Res. 2017;6:1–5.

Article  PubMed  PubMed Central  Google Scholar 

Zhou S, Lang J, Wu J, Jin Y. Massive intraperitoneal effusion caused by rare disease: a case report. Asian J Surg. 2022;2022:1015.

Google Scholar 

Li XQ, Peng XX, Gong CX. Access to orphan drugs is a challenge for sustainable management of cystinosis in China. Chin Med J. 2018;131(19):2388–9.

Article  PubMed  PubMed Central  Google Scholar 

Mu Y, Song K, Song Y. A cross-sectional study of price and affordability of drugs for rare diseases in Shandong Province, China. Int J Environ Res Public Health. 2022;19(20):13319.

Article  PubMed  PubMed Central  Google Scholar 

Rawson NSB. Canadian, European and United States new drug approval times now relatively similar. Regul Toxicol Pharmacol. 2018;96:121–6.

Article  PubMed  Google Scholar 

Hirai Y, Kinoshita H, Kusama M, Yasuda K, Sugiyama Y, Ono S. Delays in new drug applications in Japan and industrial R&D strategies. Clin Pharmacol Ther. 2010;87(2):212–8.

Article  CAS  PubMed  Google Scholar 

Shao L, Xu L, Li Q, Chakravarthy R, Yang Z, Kaitin KI. Regulatory watch: innovative drug availability in China. Nat Rev Drug Discov. 2016;15(11):739–40.

Article  CAS  PubMed  Google Scholar 

Ueyama E, Kaneko M, Narukawa M. Analysis of pediatric drug approval lag in Japan. Ther Innov Regul Sci. 2021;55(2):336–45.

Article  PubMed  Google Scholar 

Luo X, Du X, Li Z, Qian F, Yang Y. Assessment of the delay in novel anticancer drugs between China and the United States: a comparative study of drugs approved between 2010 and 2021. Clin Pharmacol Ther. 2022;113:170.

Article  PubMed  Google Scholar 

Search Orphan Drug Designations and Approvals, U.S. Food and Drug Administration. 2022. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm. Accessed 24 May 2022.

Center for Drug Evaluation, National Medical Products Administration. 2022. https://www.cde.org.cn/main/xxgk/listpage/b40868b5e21c038a6aa8b4319d21b07d. Accessed 24 May 2022.

Drug Database. YAOZH. 2022. https://www.yaozh.com/. Accessed 24 May 2022.

Tripathy S, Murthy PN, Patra BP, Mehra P, Dureja H. Challenges and prospects in Chinese pharmaceutical regulatory environment. J Gener Med. 2021;17(3):106–14.

Article  Google Scholar 

Bajaj G, Gupta M, Wang HH, et al. Challenges and opportunities with oncology drug development in China. Clin Pharmacol Ther. 2019;105:363–75.

Article  PubMed  Google Scholar 

Yamashita K, Kaneko M, Narukawa M. A significant anticancer drug approval lag between Japan and the United States still exists for minor cancers. Clin Pharmacol Ther. 2019;105:153–60.

Article  PubMed  Google Scholar 

Zhu X, Liu B. Launch delay of new drugs in China and effect on patients’ health. Clin Ther. 2020;42:1750–61.

Article  CAS  PubMed  Google Scholar 

China General Office of the State Council. Opinions on deepening the reform of the review and approval system and encouraging the innovation of drugs and medical devices. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20171009164201907.html. Accessed 24 May 2022.

Zhao S, et al. Time to raise the bar: transition rate of phase 1 programs on anticancer drugs. Cancer Cell. 2022;40:233–5.

Article  CAS  PubMed  Google Scholar 

Yao X, Ding J, Liu Y, Li P. The new drug conditional approval process in China: challenges and opportunities. Clin Ther. 2017;39(5):1040–51.

Article  PubMed  Google Scholar 

Li G, Qin Y, Xie C, Wu YL, Chen X. Trends in oncology drug Innovation in China. Nat Rev Drug Discov. 2021;20:15–6.

Article  PubMed  Google Scholar 

Shao L, Xu L, Li Q, Chakravarthy R, Yang Z, Kaitin KI. Regulatory watch: innovative drug availability in China. Nat Rev Drug Discov. 2016;15:739–40.

Article  CAS  PubMed  Google Scholar 

Li G, Liu X, Chen X. Simultaneous development of zanubrutinib in the USA and China. Nat Rev Clin Oncol. 2020;17:589–90.

Article  PubMed  PubMed Central  Google Scholar 

Zhang S, Chen L, Zhang Z, Zhao Y. Orphan drug development in China: progress and challenges. Lancet (Lond, Engl). 2019;394:1127–8.

Article  Google Scholar 

Cheng A, Xie Z. Challenges in orphan drug development and regulatory policy in China. Orphanet J Rare Dis. 2017;12:13.

Article  PubMed  PubMed Central  Google Scholar 

Xu L, Gao H, Kaitin KI, Shao L. Reforming China’s drug regulatory system. Nat Rev Drug Discov. 2018;17:858–9.

Article  CAS  PubMed  Google Scholar 

Li X, Yang Y. The drug lag issue: a 20-year review of China. Investig New Drugs. 2021;39(5):1389–98.

Article  Google Scholar 

National Medical Products Administration. Review and approval of new drugs outside of China for urgent clinical needs. 2018. https://www.nmpa.gov.cn/zhuanti/ypqxgg/ggzhcfg/20181.03017.12016.html. Accessed 24 May 2022.

Center for Drug Evaluation, National Medical Products Administration. 2022. https://www.cde.org.cn/main/news/viewInfoCommon/c4e1ef312a0a0c039a7a4ca55b91d4e8. Accessed 1 May 2023.

Hwang TJ, Kesselheim AS, Tibau A, Lee CC, Vokinger KN. Clinical benefit and expedited approval of cancer drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. JCO Oncol Pract. 2022;18: e1522.

Article  PubMed  PubMed Central  Google Scholar 

National Medical Products Administration. 2018. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20180523110601517.html. Accessed 1 May 2023.

Nakayama H, Matsumaru N, Tsukamoto K. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States. Investig New Drugs. 2019;37(5):1086–93.

Article  CAS  Google Scholar 

Xu L, Gao H, Kaitin KI, Shao L. Reforming China’s d rugregulatory system. Nat Rev Drug Discov. 2018;17:858–9.

Article  CAS  PubMed  Google Scholar 

Chaput B, Eburdery H, Crouzet C, Grolleau JL, Chavoin JP, Garrido I. Macrolane®: a severe case of calf cellulitis after modeling injection. Ann Chir Plast Esthet. 2012;57(1):83–6.

Article  CAS  PubMed  Google Scholar